Arvinas, Inc. (ARVN) Q1 FY26 Earnings Call

Vepinu approval funds a broad early-stage pipeline, but ARV102’s U.S. PSP trial remains on clinical hold.

Q1 FY26 results, source: company transcript and SEC filings
QuarterQ1 FY26
Call date2026-05-13
Length73 minutes
EPS$-0.90
EPS consensus$-0.95
Revenue$15.6M
Revenue consensus$16.6M

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

Other quarters: Q2 FY26

All ARVN earnings · Back to ARVN overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.